Summit Therapeutics Statistics
Total Valuation
SMMT has a market cap or net worth of $18.76 billion. The enterprise value is $18.08 billion.
Important Dates
The last earnings date was Thursday, May 1, 2025, after market close.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SMMT has 742.67 million shares outstanding. The number of shares has increased by 3.86% in one year.
| Current Share Class | 742.67M |
| Shares Outstanding | 742.67M |
| Shares Change (YoY) | +3.86% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 80.12% |
| Owned by Institutions (%) | 12.68% |
| Float | 116.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 51.60 |
| P/TBV Ratio | 53.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.63, with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.63 |
| Quick Ratio | 10.36 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -42.31 |
Financial Efficiency
Return on equity (ROE) is -123.93% and return on invested capital (ROIC) is -58.34%.
| Return on Equity (ROE) | -123.93% |
| Return on Assets (ROA) | -52.50% |
| Return on Invested Capital (ROIC) | -58.34% |
| Return on Capital Employed (ROCE) | -67.48% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.51M |
| Employee Count | 159 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +443.23% in the last 52 weeks. The beta is -0.95, so SMMT's price volatility has been lower than the market average.
| Beta (5Y) | -0.95 |
| 52-Week Price Change | +443.23% |
| 50-Day Moving Average | 22.03 |
| 200-Day Moving Average | 19.41 |
| Relative Strength Index (RSI) | 52.11 |
| Average Volume (20 Days) | 6,295,166 |
Short Selling Information
| Short Interest | 27.19M |
| Short Previous Month | 25.09M |
| Short % of Shares Out | 21.51% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.15 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -235.45M |
| Pretax Income | -161.69M |
| Net Income | -240.76M |
| EBITDA | -235.37M |
| EBIT | -235.45M |
| Earnings Per Share (EPS) | -$0.34 |
Full Income StatementBalance Sheet
The company has $361.32 million in cash and $6.45 million in debt, giving a net cash position of $354.87 million or $0.48 per share.
| Cash & Cash Equivalents | 361.32M |
| Total Debt | 6.45M |
| Net Cash | 354.87M |
| Net Cash Per Share | $0.48 |
| Equity (Book Value) | 344.33M |
| Book Value Per Share | 0.46 |
| Working Capital | 335.87M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$173.14 million and capital expenditures -$557,000, giving a free cash flow of -$173.70 million.
| Operating Cash Flow | -173.14M |
| Capital Expenditures | -557,000 |
| Free Cash Flow | -173.70M |
| FCF Per Share | -$0.23 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |